@article{Gregor Verhoef_Tadeusz Robak_Huiqiang Huang_Halyna Pylypenko_Noppadol Siritanaratkul_Juliana Pereira_Johannes Drach_Jiri Mayer_Rumiko Okamoto_Lixia Pei_Brendan Rooney_Andrew Cakana_Helgi van de Velde_Franco Cavalli_2017, place={Pavia, Italy}, title={Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study}, volume={102}, url={https://haematologica.org/article/view/8069}, DOI={10.3324/haematol.2016.152496}, abstractNote={In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 <em>versus</em> 14.4 months with R-CHOP; <em>P</em><0.001). This <em>post-hoc</em> analysis evaluated the association between the improved outcomes and quality of responses achieved with VR-CAP <em>versus</em> R-CHOP in LYM-3002. Patients were randomized to six to eight 21-day cycles of VR-CAP or R-CHOP. Outcomes included progression-free survival, duration of response (both assessed by an independent review committee), and time to next anti-lymphoma treatment, evaluated by response (complete response/unconfirmed complete response and partial response), MIPI risk status, and maximum reduction of lymph-node measurements expressed as the sum of the product of the diameters. Within each response category, the median progression-free survival was longer for patients given VR-CAP than for those given R-CHOP (complete response/unconfirmed complete response: 40.9 <em>versus</em> 19.8 months; partial response: 17.1 <em>versus</em> 11.7 months, respectively); similarly, the median time to next anti-lymphoma treatment was longer among the patients given VR-CAP than among those treated with R-CHOP (complete response/unconfirmed complete response: not evaluable <em>versus</em> 26.6 months; partial response: 35.3 <em>versus</em> 24.3 months). Within the complete/unconfirmed complete and partial response categories, improvements in progression-free survival, duration of response and time to next anti-lymphoma treatment were more pronounced in patients with low-and intermediate-risk MIPI treated with VR-CAP than with R-CHOP. In each response category, more VR-CAP than R-CHOP patients had a sum of the product of the diameters nadir of 0 during serial radiological assessments. Results of this <em>post-hoc</em> analysis suggest a greater duration and quality of response in patients treated with VR-CAP in comparison with those treated with R-CHOP, with the improvements being more evident in patients with low- and intermediate-risk MIPI. <em>LYM-3002 <a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a>: <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT00722137&amp;atom=%2Fhaematol%2F102%2F5%2F895.atom">NCT00722137</a></em&gt;.}, number={5}, journal={Haematologica}, author={Gregor Verhoef and Tadeusz Robak and Huiqiang Huang and Halyna Pylypenko and Noppadol Siritanaratkul and Juliana Pereira and Johannes Drach and Jiri Mayer and Rumiko Okamoto and Lixia Pei and Brendan Rooney and Andrew Cakana and Helgi van de Velde and Franco Cavalli}, year={2017}, month={Apr.}, pages={895-902} }